Rosenberg, Germany - July 20, 2016 - JRS PHARMA, headquartered in Germany, has entered into a joint venture agreement with SSP, headquartered in Chongqing, China, for the commercialization of povidone products. The new JV company is Star-Tech & JRS Specialty Products.
Equipped with innovative technology and a state-of-the-art GMP-compliant production facility, Star-Tech & JRS Specialty Products specializes in the manufacture of high quality povidones with CEP certification for life sciences applications.
JRS PHARMA, an innovative leader in the development, manufacture, and distribution of high quality pharmaceutical and nutraceutical excipients, will assume the overall quality responsibility for all VIVAPHARM® povidone products through final quality checks in the newly established Analytic Competence Center in Germany. JRS PHARMA will also manage all R&D, marketing, and sales of povidone products for the health science industry.
This strategic alliance expands the JRS PHARMA product portfolio, resulting in an even more comprehensive solution to its customers’ needs. The joint venture capitalizes on JRS PHARMA’s strong global presence, along with the technical support offered by four Technical Competence Centers worldwide.
Join us at CPhI Worldwide this October to learn more about our all new Povidone product line.
October 4-6, 2016
Schedule a meeting: ExcipientsService@JRSPharma.de